Paone G, Spencer T, Silverman N A
Division of Cardiac and Thoracic Surgery, Henry Ford Hospital, Detroit, Mich. 48202.
Surgery. 1994 Oct;116(4):672-7; discussion 677-8.
Most patients undergoing coronary artery bypass surgery receive homologous blood transfusions despite the availability of multiple pharmacologic and blood salvage conservation strategies.
The efficacy of defining strict transfusion criteria as the sole blood conservation strategy was adjudicated prospectively by comparing homologous blood product usage in 314 consecutive patients undergoing isolated primary coronary artery bypass surgery (group 2) with a retrospective group of 947 consecutive patients undergoing the same procedure but transfused without protocol (group 1).
The incidence of red cell transfusion and plasma transfusion decreased from 40.5% to 25.8% and 23.8% to 13.4% in groups 1 and 2, respectively (p < 0.001). The percentage of patients receiving no homologous blood products increased from 47.6% in group 1 to 68.5% in group 2 (p < 0.001). Decreasing body weight and preoperative hematocrit were found to be highly significant predictors of the need for red blood cell transfusion (p < 0.001). Significant postoperative determinants included intensive care unit and hospital length of stay and reoperation for bleeding (p < 0.001 each).
Because major determinant of homologous blood transfusion during coronary bypass surgery is the predictable and unavoidable dilution of a small red cell mass that occurs when instituting cardiopulmonary bypass, adherence to defined transfusion criteria alone is a simple, safe, and effective strategy for decreasing blood product utilization.
尽管有多种药物和血液回收保存策略,但大多数接受冠状动脉搭桥手术的患者仍接受同源输血。
通过比较314例连续接受单纯初次冠状动脉搭桥手术的患者(第2组)与947例连续接受相同手术但无输血方案的回顾性患者组(第1组)中同源血制品的使用情况,前瞻性地判定将严格输血标准定义为唯一血液保护策略的疗效。
第1组和第2组的红细胞输血发生率和血浆输血发生率分别从40.5%降至25.8%和从23.8%降至13.4%(p<0.001)。未接受同源血制品的患者百分比从第1组的47.6%增至第2组的68.5%(p<0.001)。发现体重减轻和术前血细胞比容是红细胞输血需求的高度显著预测因素(p<0.001)。术后的显著决定因素包括重症监护病房和住院时间以及因出血再次手术(每项p<0.001)。
由于冠状动脉搭桥手术期间同源输血的主要决定因素是在建立体外循环时发生的可预测且不可避免的小红细胞量稀释,仅遵守既定输血标准是一种减少血制品使用的简单、安全且有效的策略。